Point72 Asset Management
CCCC icon

Point72 Asset Management’s C4 Therapeutics CCCC Stock Holding History

Point72 Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$720K – 2088
2024
Q4 		$720K Buy
+200,000
New +$994K ﹤0.01% 1561

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management's CCCC Position: Q2 2026 in Review

Point72 Asset Management increased its C4 Therapeutics (CCCC) stake by 2.9% in Q2 2026, buying an estimated $16.7K and bringing the position to 173,965 shares worth $812K. The position accounts for ﹤0.01% of the portfolio, ranked #2943.

Point72 Asset Management first reported a position in CCCC in Q2 2021 and has held it in 15 quarters since. The position peaked at $18M in Q4 2025. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Point72 Asset Management held 173,965 shares of C4 Therapeutics worth $812K as of Q2 2026.
  • Point72 Asset Management bought 4,869 C4 Therapeutics shares in Q2 2026, an estimated $16.7K.
  • C4 Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2943 holding.
  • Point72 Asset Management first reported a position in C4 Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • Point72 Asset Management's C4 Therapeutics position peaked at $18M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.